This enhanced immunogenicity translated into robust anti-tumor responses in vivo, including DC maturation, the increased infiltration of CD8+ T lymphocytes, and a reduction in Tregs within the tumor microenvironment. The gene discussed is CD8A; the disease is neoplasm.